Dentsply Sirona Inc. USDC – Southern District of New York december 10, 2024 CLASS PERIOD: december 1, 2022 – november 6, 2024LEAD PLAINTIFF DEADLINE: january 27, 2024 Please complete the form below to contact Kaplan Fox regarding the Dentsply Sirona Investigation: Join a Case First Name * Last Name * Email Address * Phone Number * Ticker Symbol Or Company Name * Please Insert Your Estimation Of Losses In USD * Are you a current or former employee of the company mentioned having traded above? * Yes No Captcha Submit If you are human, leave this field blank. Join Investigation Principle Contacts Pamela MayerPMayer@kaplanfox.comLaurence D. KingLKing@kaplanfox.com Kaplan Fox & Kilsheimer LLP Alerts Investors to a Securities Class Action Against DENTSPLY SIRONA Inc. (XRAY) – Deadline is January 27, 2025 Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against DENTSPLY SIRONA Inc. (“DENTSPLY” or the “Company”) (NASDAQ: XRAY) on behalf of investors that purchased or otherwise acquired DENTSPLY securities between December 1, 2022 and November 6, 2024 (the “Class Period”). CLICK HERE TO JOIN THE CASE If you are an investor in DENTSPLY and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing pmayer@kaplanfox.com or by calling (646) 315-9003. DEADLINE REMINDER: If you are a member of the proposed Class, you may move the court no later than January 27, 2025 to serve as a lead plaintiff for the purported class. If you have losses we encourage you to contact us to learn more about the lead plaintiff process. On October 24, 2024, DENTSPLY issued a press release “announc[ing] the voluntary suspension of sales and marketing of its Byte Aligners and Impression Kits while the Company conducts a review of certain regulatory requirements related to these products.” The press release also states that “[t]he Company’s decision was made in consultation with the U.S. Food and Drug Administration (FDA).” Following this news, the price of DENTSPLY’s stock fell $1.10 per share, or 4.5%, to close at $23.31 per share on October 25, 2024. Then, on November 6, 2024, in connection with reporting third quarter financial results, DENTSPLY issued a press release revising its 2024 outlook to reflect that organic sales are expected to be down 3.5% to 2.5% year-over-year compared to its prior outlook that organic sales would be down 1% to flat. Following this news, the price of DENTSPLY’s stock fell $6.72 per share, about 28%, to close at $17.26 per share on November 7, 2024. WHY CONTACT KAPLAN FOX Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey. With over 50 years of experience in securities litigation, Kaplan Fox offers the professional experience and track record that clients demand. Through prosecuting cases on the federal and state levels, Kaplan Fox has successfully shaped the law through winning many important decisions on behalf of our clients. For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at www.kaplanfox.com. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. If you have any questions about this Notice, your rights, or your interests, please contact: CONTACT: Pamela A. MayerKAPLAN FOX & KILSHEIMER LLP800 Third Avenue, 38th FloorNew York, New York 10022(646) 315-9003pmayer@kaplanfox.com Laurence D. KingKAPLAN FOX & KILSHEIMER LLP1999 Harrison Street, Suite 1560Oakland, California 94612(415) 772-4704lking@kaplanfox.com Connect with Kaplan Fox. Receive a complimentary case review now. Contact Us Celsius Holdings, Inc. See the Case Dentsply Sirona Inc. See the Case Western Asset Macro Opportunities Fund See the Case Franklin Resources, Inc. See the Case Customers Bancorp, Inc. See the Case Rentokil Initial plc See the Case Warner Bros Discovery, Inc. See the Case Applied Therapeutics, Inc. See the Case Zeta Global Holdings Corp. See the Case Macy’s, Inc. See the Case Quanterix Corp See the Case MediaAlpha, Inc. See the Case
